Gerald V Naccarelli

Summary

Affiliation: Pennsylvania State University
Country: USA

Publications

  1. ncbi CHADS2 and CHA2DS2-VASc risk factors to predict first cardiovascular hospitalization among atrial fibrillation/atrial flutter patients
    Gerald V Naccarelli
    Penn State Heart and Vascular Institute, Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, USA
    Am J Cardiol 109:1526-33. 2012
  2. ncbi Rates and implications for hospitalization of patients ≥65 years of age with atrial fibrillation/flutter
    Gerald V Naccarelli
    Penn State Heart and Vascular Institute, Milton S Hershey Medical Center, Penn State University, Hershey, Pennsylvania, USA
    Am J Cardiol 109:543-9. 2012
  3. ncbi Increasing prevalence of atrial fibrillation and flutter in the United States
    Gerald V Naccarelli
    Pennsylvania State Heart and Vascular Institute, Milton S Hershey Medical Center, Pennsylvania State University, Hershey, Pennsylvania, USA
    Am J Cardiol 104:1534-9. 2009
  4. ncbi Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States
    Gerald V Naccarelli
    Penn State Heart and Vascular Institute, Milton S Hershey Medical Center, Penn State University, Hershey, Pennsylvania 17033, USA
    Clin Cardiol 33:270-9. 2010
  5. ncbi Optimizing the management of atrial fibrillation: focus on current guidelines and the impact of new agents on future recommendations
    Gerald V Naccarelli
    Division of Cardiology, Penn State Heart and Vascular Institute, Hershey, PA 17033, USA
    J Cardiovasc Pharmacol Ther 15:244-56. 2010
  6. ncbi A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission
    Gerald V Naccarelli
    Heart and Vascular Institute, Penn State University College of Medicine, Hershey, PA, USA
    J Cardiovasc Pharmacol Ther 15:24S-30S. 2010
  7. ncbi Post-ATHENA and beyond
    Gerald V Naccarelli
    Heart and Vascular Institute, Penn State University College of Medicine, Hershey, PA, USA
    J Interv Card Electrophysiol 31:55-60. 2011
  8. ncbi New antiarrhythmic treatment of atrial fibrillation
    Gerald V Naccarelli
    Penn State University Heart and Vascular Institute, The Electrophysiology Program, Penn State University College of Medicine, The Milton S Hershey Medical Center, 500 University Dr, Room H 1 511, Hershey, PA 17033, USA
    Expert Rev Cardiovasc Ther 5:707-14. 2007
  9. ncbi Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter
    Javier E Banchs
    Penn State Heart and Vascular Institute, Milton S Hershey Medical Center, Penn State University, 500 University Drive, P O Box 850, Hershey, PA, 17033 0850, USA
    J Interv Card Electrophysiol 23:111-5. 2008
  10. ncbi Intracardiac echocardiography in complex cardiac catheter ablation procedures
    Javier E Banchs
    Penn State Heart and Vascular Institute, Penn State University College of Medicine, 500 University Drive, H047, Hershey, PA 17033, USA
    J Interv Card Electrophysiol 28:167-84. 2010

Detail Information

Publications39

  1. ncbi CHADS2 and CHA2DS2-VASc risk factors to predict first cardiovascular hospitalization among atrial fibrillation/atrial flutter patients
    Gerald V Naccarelli
    Penn State Heart and Vascular Institute, Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, USA
    Am J Cardiol 109:1526-33. 2012
    ..In conclusion, CHADS(2) and CHA(2)DS(2)-VASc scores were predictive of first CV hospitalization in patients with AF or AFL and may be helpful in identifying "at-risk" patients and guiding therapy...
  2. ncbi Rates and implications for hospitalization of patients ≥65 years of age with atrial fibrillation/flutter
    Gerald V Naccarelli
    Penn State Heart and Vascular Institute, Milton S Hershey Medical Center, Penn State University, Hershey, Pennsylvania, USA
    Am J Cardiol 109:543-9. 2012
    ..Measures that lower inpatient admission rates, particularly readmission rates, may reduce the increasing cost of treating patients with AF or AFL with Medicare supplemental insurance...
  3. ncbi Increasing prevalence of atrial fibrillation and flutter in the United States
    Gerald V Naccarelli
    Pennsylvania State Heart and Vascular Institute, Milton S Hershey Medical Center, Pennsylvania State University, Hershey, Pennsylvania, USA
    Am J Cardiol 104:1534-9. 2009
    ..The current and projected increases in the prevalence of AF are greater than predicted by a previous sentinel study and might reflect more than the aging of the population...
  4. ncbi Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States
    Gerald V Naccarelli
    Penn State Heart and Vascular Institute, Milton S Hershey Medical Center, Penn State University, Hershey, Pennsylvania 17033, USA
    Clin Cardiol 33:270-9. 2010
    ..001) in patients with atrial fibrillation (AF) and atrial flutter (AFL)...
  5. ncbi Optimizing the management of atrial fibrillation: focus on current guidelines and the impact of new agents on future recommendations
    Gerald V Naccarelli
    Division of Cardiology, Penn State Heart and Vascular Institute, Hershey, PA 17033, USA
    J Cardiovasc Pharmacol Ther 15:244-56. 2010
    ....
  6. ncbi A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission
    Gerald V Naccarelli
    Heart and Vascular Institute, Penn State University College of Medicine, Hershey, PA, USA
    J Cardiovasc Pharmacol Ther 15:24S-30S. 2010
    ..Dronedarone is a novel, multichannel blocking antiarrhythmic agent that may have some pleiotropic effects in addition to its ability to suppress and maintain sinus rhythm and control the rate during AF/AFL recurrences...
  7. ncbi Post-ATHENA and beyond
    Gerald V Naccarelli
    Heart and Vascular Institute, Penn State University College of Medicine, Hershey, PA, USA
    J Interv Card Electrophysiol 31:55-60. 2011
    ..These results raise the hypothesis that many of the benefits noted from this trial may be secondary to more than the antiarrhythmic properties of dronedarone. Future studies will clarify the mechanisms of this beneficial effect...
  8. ncbi New antiarrhythmic treatment of atrial fibrillation
    Gerald V Naccarelli
    Penn State University Heart and Vascular Institute, The Electrophysiology Program, Penn State University College of Medicine, The Milton S Hershey Medical Center, 500 University Dr, Room H 1 511, Hershey, PA 17033, USA
    Expert Rev Cardiovasc Ther 5:707-14. 2007
    ..Future studies will clarify the role of these drugs in treating AF...
  9. ncbi Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter
    Javier E Banchs
    Penn State Heart and Vascular Institute, Milton S Hershey Medical Center, Penn State University, 500 University Drive, P O Box 850, Hershey, PA, 17033 0850, USA
    J Interv Card Electrophysiol 23:111-5. 2008
    ..It is not known, however, whether pharmacological conversion with dofetilide predicts maintenance of sinus rhythm. In addition, there is limited information comparing the efficacy of dofetilide in persistent versus paroxysmal AF/AFL...
  10. ncbi Intracardiac echocardiography in complex cardiac catheter ablation procedures
    Javier E Banchs
    Penn State Heart and Vascular Institute, Penn State University College of Medicine, 500 University Drive, H047, Hershey, PA 17033, USA
    J Interv Card Electrophysiol 28:167-84. 2010
    ....
  11. ncbi Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials
    Gerald V Naccarelli
    Division of Cardiology and the Penn State Cardiovascular Center, Penn State University College of Medicine, The Milton S Hershey Medical Center, Hershey, Pennsylvania 17033, USA
    Am J Cardiol 91:15D-26D. 2003
    ..In post-myocardial infarction patients, sotalol is an additional agent to consider for treatment of AF in this setting...
  12. ncbi Atrial fibrillation in heart failure: prognostic significance and management
    Gerald V Naccarelli
    Division of Cardiology and the Penn State Cardiovascular Center, Penn State College of Medicine, Hershey, Pennsylvania 17033, USA
    J Cardiovasc Electrophysiol 14:S281-6. 2003
    ..The article presents an overview of atrial fibrillation in patients with heart failure and reviews the prevalence, prognostic significance, and efficacy of various antiarrhythmic agents for the conversion and maintenance of sinus rhythm...
  13. ncbi Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies
    Giselle A Baquero
    Heart and Vascular Institute, Penn State College of Medicine, Hershey, Pennsylvania, USA
    J Cardiovasc Electrophysiol 23:296-301. 2012
    ..Dofetilide has only been approved for the treatment of atrial fibrillation. The role of dofetilide in the control of ventricular arrhythmias in patients with an ICD has not been established...
  14. ncbi Vernakalant: pharmacology electrophysiology, safety and efficacy
    Gerald V Naccarelli
    Division of Cardiology, Penn State University Heart and Vascular Institute, Penn State University College of Medicine, Hershey, PA 17033, USA
    Drugs Today (Barc) 44:325-9. 2008
    ..In addition, preliminary data suggest that it could also suppress recurrences when used orally. This paper reviews the pharmacology, electrophysiology, efficacy and safety of intravenous and oral vernakalant...
  15. ncbi Selection of drugs in pursuit of rate control strategy
    Soraya M Samii
    Division of Cardiology, Pennsylvania State Cardiovascular Center, Penn State University College of Medicine, The Milton S. Hershey Medical Center, Hershey, PA 17033, USA
    Prog Cardiovasc Dis 48:146-52. 2005
    ..Adequate rate control can be achieved by atrioventricular nodal blocking agents both in the acute and chronic settings. In refractory patients, other methods such as atrioventricular node ablation can be used to control rate...
  16. ncbi A review of clinical trials assessing the efficacy and safety of newer antiarrhythmic drugs in atrial fibrillation
    Gerald V Naccarelli
    Division of Cardiology and the Pennsylvania State Cardiovascular Center, Penn State University College of Medicine, Hershey, PA 17033, USA
    J Interv Card Electrophysiol 9:215-22. 2003
    ..Newer antiarrhythmic agents, some with novel mechanisms of action, will add to the pharmacologic armamentarium in treating atrial fibrillation...
  17. ncbi Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation
    Gerald V Naccarelli
    Penn State University College of Medicine, Division of Cardiology, 500 University Dr Room H 1 511, Hershey, PA 17033, USA
    Expert Opin Investig Drugs 17:805-10. 2008
    ..In addition, this drug has important rate-dependent sodium channel blocking properties...
  18. ncbi Atrial fibrillation in patients with heart failure
    B John Hynes
    Division of Cardiology, Penn State University College of Medicine, Hershey, PA 17033, USA
    Curr Opin Cardiol 18:32-8. 2003
    ....
  19. ncbi Does carvedilol have antiarrhythmic properties?
    Gerald V Naccarelli
    Division of Cardiology, Penn State University College of Medicine, Hershey, PA 17033, USA
    Nat Clin Pract Cardiovasc Med 2:338-9. 2005
  20. ncbi Post myocardial infarction, left ventricular dysfunction, and the expanding role of cardiac implantable electrical devices
    Gerald V Naccarelli
    Division of Cardiology, Pennsylvania State University, College of Medicine, The Milton S Hershey Medical Center, Hershey, Pennsylvania 17033, USA
    Clin Cardiol 28:I51-7. 2005
    ..Implanted devices must be followed up appropriately, with periodic interrogation and program adjustment to reduce the risk for pacing-induced desynchronization and to optimize hemodynamic benefit...
  21. ncbi Complications of biventricular pacing
    Luna Bhatta
    Division of Cardiology, Penn State Cardiovascular Center, Pennsylvania State College of Medicine, Hershey, USA
    Curr Opin Cardiol 19:31-5. 2004
    ..This review summarizes the data derived from major clinical trials about the complications related to implantation, hardware, and programming of biventricular devices...
  22. ncbi Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry)
    Peter R Kowey
    Jefferson Medical College, Philadelphia, Pennsylvania, USA
    Am J Cardiol 105:1130-4. 2010
    ..In conclusion, these results suggest that continued physician education of appropriate anticoagulation use in patients with AF is needed...
  23. ncbi Atrial fibrillation and the expanding role of catheter ablation: do antiarrhythmic drugs have a future?
    Gerald V Naccarelli
    Penn State University Heart and Vascular Institute, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA
    J Cardiovasc Pharmacol 52:203-9. 2008
    ....
  24. ncbi Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter
    Gerald V Naccarelli
    Penn State Hershey Heart and Vascular Institute, Cardiac Electrophysiology Program, Hershey, PA, USA
    Clin Med Insights Cardiol 5:103-19. 2011
    ..In addition, the recent results of the PALLAS trial suggest that dronedarone should not be used in the long-term treatment of patients with permanent AF...
  25. ncbi Antiadrenergic therapy in the control of atrial fibrillation
    Gerald V Naccarelli
    Division of Cardiology, Penn State University, College of Medicine, The Milton S Hershey Medical Center, Hershey, PA
    J Cardiovasc Pharmacol Ther 10:S33-43. 2005
    ..Carvedilol is effective, alone or in combination, with digoxin in such heart failure patients with AF, and has been shown to reduce mortality risk in patients with chronic heart failure during prolonged therapy...
  26. ncbi Role of intracardiac ultrasound in interventional electrophysiology
    B John Hynes
    Division of Cardiology and Pennsylvania State Cardiovascular Center, Pennsylvania State University, College of Medicine, Hershey 17033, USA
    Curr Opin Cardiol 19:52-7. 2004
    ..SUMMARY: A comprehensive look is provided at the history and development of this new technology along with the most recent applications of ICE in interventional electrophysiology...
  27. ncbi Distal balloon occlusion allows epicardial lead placement in a tortuous branch of the great cardiac vein
    Parag Patel
    Penn State Heart and Vascular Institute, Milton S Hershey Medical Center, Hershey, PA, USA
    J Interv Card Electrophysiol 25:159-61. 2009
    ..This approach can be used in navigating lead placement to branches thought to be unreachable. Techniques such as this can decrease the failure rate of CRT implants...
  28. ncbi Device therapies in the post-myocardial infarction patient with left ventricular dysfunction
    Alan H Kadish
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Am J Cardiol 102:29G-37G. 2008
    ..Further risk stratification studies of post-MI LVD patients will allow ICD therapy to be applied in a more cost-effective manner...
  29. ncbi Paroxysmal atrioventricular block following a ventricular premature beat
    Javier E Banchs
    Heart and Vascular Institute, Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pennsylvania 17033-0850, USA
    J Cardiovasc Electrophysiol 18:230. 2007
  30. ncbi Does it make sense to train plumbers as electricians?
    Gerald V Naccarelli
    Division of Cardiology and the Pennsylvania State Cardiovascular Center, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA
    J Am Coll Cardiol 44:1358-60. 2004
    ..In this paper, a pathway is presented that would combine training in HF/transplantation and cardiac implantable electrical devices...
  31. ncbi Entrainment of ventricular tachycardia with a permanent biventricular pacemaker
    Jerry C Luck
    Department of Medicine, Section of Cardiology, Milton S Hershey Medical Center, Pennsylvania State University 17003, USA
    J Interv Card Electrophysiol 7:105-11. 2002
    ..The entrance and exit points of the loop for VT appeared to rest between the two pacing sites in the intraventricular septum. This case illustrates one of the sensing limitations of today's biventricular pacing defibrillator systems...
  32. ncbi The Brugada syndrome
    Gerald V Naccarelli
    Division of Cardiology, Cardiovascular Center, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA
    Curr Opin Cardiol 17:19-23. 2002
    ..Because of the poor prognosis of such patients, symptomatic patients should be treated with an implantable cardioverter-defibrillator...
  33. ncbi Maintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablation
    Gerald V Naccarelli
    Hershey Medical Center, Division of Cardiology, 500 University Drive, Hershey, PA 17033, USA
    Curr Cardiol Rep 4:418-25. 2002
    ..Hybrid therapy using drugs in combination with nonpharmacologic approaches will be used more frequently in the future for refractory patients...
  34. ncbi Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation
    Gerald V Naccarelli
    Penn State Heart and Vascular Institute, Hershey, Pennsylvania 17033 3907, USA
    Vasc Health Risk Manag 5:783-91. 2009
    ..Large-scale hypertension trials and heart failure trials have indicated the potential value of angiotensin II receptor blockers in the treatment of AF...
  35. ncbi Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction
    Gerald V Naccarelli
    Division of Cardiology, Cardiovascular Center, Penn State University College of Medicine, The Milton S Hershey Medical Center, Hershey, Pennsylvania 17033, USA
    Clin Cardiol 28:165-73. 2005
    ..Recent trials of implantable cardioverter-defibrillators added to pharmacologic therapy, especially beta blockers, have shown a further reduction in arrhythmic deaths in these patients...
  36. ncbi Advances in the treatment of atrial fibrillation: the future is now
    Gerald V Naccarelli
    Division of Cardiology and Cardiovascular Center, Pennsylvania State University College of Medicine, The Milton S. Hershey Medical Center, Hershey, PA 17033, USA
    J Interv Card Electrophysiol 10:77-8. 2004
  37. ncbi Implantable cardioverter-defibrillators: expanding indications
    Gerald V Naccarelli
    Division of Cardiology and Cardiovascular Center, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA
    Curr Opin Cardiol 19:317-22. 2004
    ..This article reviews multiple secondary and primary prevention trials that have expanded the indications for implantable cardioverter-defibrillators (ICDs)...
  38. ncbi Left ventricular aneurysm as a consequence of hypertrophic obstructive cardiomyopathy
    Patrick H McNulty
    Cardiovascular Center, Penn State College of Medicine, Hershey, Pennsylvania 17033, USA
    Catheter Cardiovasc Interv 55:385-8. 2002
  39. ncbi Biventricular pacing in congestive heart failure: a boost toward finer living
    Jerry C Luck
    Pennsylvania State University, Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033-0850, USA
    Curr Opin Cardiol 17:96-101. 2002
    ..The acute hemodynamic studies suggest that resynchronization pacing therapy may predict a positive long-term benefit for many patients with congestive heart failure...